Drilldown: Medicines

None · Codeine · 1,4-Butanediol · 1B-LSD · 1cP-LSD · 1P-LSD · 1V-LSD · 2-AI · 2-FA · 2-FDCK · 2-FMA · 25B-NBOH · 25B-NBOMe · 25C-NBOH · 25C-NBOMe · 25I-NBOH · 25I-NBOMe · 25N-NBOMe · 2C-B · 2C-B-FLY

Other values:

Search

None (2) · (multiple, generic dominant) (1) · Ritalin, Ritalin LA, Concerta, Metadate CD, Daytrana, Quillivant XR (1)

Analgesic (2) · Classic Psychedelic (1) · NDRI (1) · Opioid (2) · Phenethylamine (1) · Prodrug (1) · Psychostimulant (1) · Research material (1)

5-HT2A agonist (1) · Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) · Norepinephrine–dopamine reuptake inhibition (DAT, NET) (1) · Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1)

None (2) · ADHD, narcolepsy (1) · Mild to moderate pain; cough suppression (low-dose). (1)

None (3) · Adult: 15–60 mg every 4 hours as needed. (1)

None (3) · Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)

None (3) · 360 mg/day (1)

None (2) · Oral (1) · PO (only formulation marketed in the US). (1) · transdermal (1)

None (2) · 20–60 min (oral) (1) · 30–60 min (PO) (1)

None (2) · 4–6 hours (1) · IR 3–5 h; LA/SR 6–8 h; Concerta 10–12 h; Daytrana ~9 h wear time (1)

None (2) · 2.5–3 hours (1) · 2–3 h (parent compound) (1)

None (2) · ~30% (high first-pass) (1) · ~50% (variable, CYP2D6-dependent for analgesic effect). (1)

None (2) · Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) · Pregnancy categories were retired by FDA in 2015. Limited reproductive data with small observational signal for cardiac malformations; risk-benefit decision, with many patients deferring ADHD treatment during pregnancy. See pregnancy_details for the full discussion. (1)

None (2) · Schedule II (1) · US Schedule II (single-entity); Schedule III–V (combination products by content). (1)